Universal donor stem cell therapy developed to treat degenerative brain diseases
'This is the first time stem cells have been engineered to become universal donors for cell therapy targeting diseases of the central nervous system.'
'This is the first time stem cells have been engineered to become universal donors for cell therapy targeting diseases of the central nervous system.'
'This is the first time stem cells have been engineered to become universal donors for cell therapy targeting diseases of the central nervous system.'
New York: US scientists have developed universal donor stem cells that could one day provide lifesaving therapy to children with lethal brain conditions, such as Canavan disease, as well as to people with other degenerative diseases, such as Alzheimer's and multiple sclerosis.
The team at Beckman Research Institute of City of Hope in California used a technique that allowed engineered hypoimmunogenic cells from a healthy donor to be transplanted into a humanised disease model without activating the immune system to kill the foreign therapeutic.
"The off-the-shelf approach can easily be extended to improve the quality of life of cancer patients who are experiencing cognitive impairment or impaired motor function as a side effect of chemotherapy or radiation," said Yanhong Shi, chair of the Department of Neurodegenerative Diseases and Professor in Neuroscience at the Institute.
This is the first time stem cells have been engineered to become universal donors for cell therapy targeting diseases of the central nervous system, said Shi who has been working on this research for 12 years.
This 'off-the-shelf' approach can provide patients who need cell therapy with lifesaving treatments three to six months earlier.
In the study, recently published in the journal Advanced Science, the researchers engineered healthy human skin cells containing the functional aspartoacylase (ASPA) gene into induced pluripotent stem cells (iPSCs) and then differentiated the iPSCs into oligodendroglial progenitor cells, the precursor cells that produce myelin, an insulating sheath that wraps around nerve fibres.
Like a bullet train, myelin sheaths facilitate the light-speed transport of information along neuronal axons.
The treated Canavan disease animal models exhibited increased ASPA activity compared to the control mice and had a reduction in the toxic accumulation of the metabolite N-acetyl-L-aspartate (NAA) in the brain.
Too much NAA has been linked to impaired motor function, mental deficiencies and premature death.
As a result, the treated mice exhibited increased myelination and vastly improved motor function. Importantly, the universal donor cells were able to evade immune attack from the recipient mice.